<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 9, 2025</title>
<meta name="color-scheme" content="light dark" />
<style>
  :root { --maxw: 800px; }
  html { -webkit-text-size-adjust: 100%; }
  body { margin: 0; padding: 0; font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji; line-height: 1.6; font-size: 18px; }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

<span title="Standards of Care">Los Estándares de Atención</span> en Diabetes de la <span title="American Diabetes Association">Asociación Americana de Diabetes</span> (ADA) <span title="indicate that">indican que</span> la prevención, la reducción del <span title="cardiorenal risk">riesgo cardiorrenal</span> y el <span title="treatment of obesity">tratamiento de la obesidad</span> <span title="are key objectives">son objetivos clave</span>. <span title="The Standards now consider">Los Estándares ahora consideran</span> la diabetes como parte de la <span title="cardiorenal-metabolic health">salud cardiorrenal-metabólica</span> (CKM). <span title="They point out that">Señalan que</span> la glucosa, la presión arterial, los lípidos, el peso, la función renal y el <span title="risk of heart failure">riesgo de insuficiencia cardíaca</span> <span title="are all related">están todos relacionados</span>. <span title="They are not just separate problems">No son solo problemas separados</span>.

1. <span title="Early risk stratification">Estratificación temprana del riesgo</span>: <span title="Adults with">Los adultos con</span> sobrepeso/obesidad, prediabetes, NAFLD o <span title="established atherosclerotic cardiovascular disease">enfermedad cardiovascular aterosclerótica (ASCVD)</span>/<span title="chronic kidney disease">enfermedad renal crónica (ERC)</span> establecida <span title="should receive">deben recibir</span> <span title="earlier and more frequent evaluations">evaluaciones más tempranas y frecuentes</span> para <span title="dysglycemia and CKM risk">disglucemia y riesgo CKM</span>. <span title="Use risk tools">Use herramientas de riesgo</span> para ASCVD y riñón <span title="when possible">cuando sea posible</span>.

2. <span title="Continuous glucose monitoring (CGM) beyond intensive insulin">Monitoreo continuo de glucosa (MCG) más allá de la insulina intensiva</span>: <span title="The ADA Standards support">Los Estándares de la ADA apoyan</span> el <span title="use of CGM">uso de MCG</span> para la <span title="majority of people with">mayoría de las personas con</span> diabetes tipo 1 y muchos pacientes con diabetes tipo 2 <span title="treated with insulin">tratados con insulina</span>. <span title="CGM can also be used">También puede usarse MCG</span> en algunos pacientes con diabetes tipo 2 <span title="not treated with insulin">no tratados con insulina</span> que <span title="are at high risk of hypoglycemia">tienen alto riesgo de hipoglucemia</span> o <span title="when A1C does not match">cuando el A1C no coincide</span> con los <span title="glucose data">datos de glucosa</span>.

3. <span title="Time in range (TIR)">Tiempo en rango (TIR)</span>: <span title="For patients who use CGM">Para los pacientes que usan MCG</span>, el <span title="goal is a TIR">objetivo es un TIR</span> ≥70% (70–180 mg/dL) y <span title="time below range">tiempo por debajo del rango</span> <4%. <span title="These are the main glycemic outcomes">Estos son los principales desenlaces glucémicos</span> <span title="related to microvascular risk">relacionados con el riesgo microvascular</span> y <span title="complement A1C">complementan el A1C</span>.

4. <span title="Pharmacotherapy focused on weight and risk">Farmacoterapia enfocada en peso y riesgo</span>: <span title="In adults with">En adultos con</span> diabetes tipo 2 y sobrepeso/obesidad, <span title="try to use">intente usar</span> <span title="medications that help">medicamentos que ayuden</span> a <span title="lose weight">perder peso</span> y <span title="provide cardiovascular and renal benefits">brinden beneficios cardiovasculares y renales</span>, como los <span title="GLP-1 receptor agonists">agonistas del receptor GLP-1</span> y los <span title="SGLT2 inhibitors">inhibidores de SGLT2</span>, <span title="when cost and access allow">cuando el costo y el acceso lo permitan</span>. <span title="Use them earlier">Úselos antes</span> en personas con <span title="high risk of ASCVD">alto riesgo de ASCVD</span>, insuficiencia cardíaca o ERC, <span title="sometimes even if">a veces incluso si</span> el A1C basal <span title="is at target">está en objetivo</span> o <span title="do not use metformin">no usan metformina</span>.

---
DIALOGUE

Narrator: <span title="Today, Dr. Smith talks with Mr. Lee about diabetes care">Hoy, el Dr. Smith habla con el Sr. Lee sobre el cuidado de la diabetes</span>.
Physician: <span title="Hello, Mr. Lee">Hola, Sr. Lee</span>. <span title="I see that you have">Veo que tiene</span> diabetes tipo 2 y <span title="some overweight">algo de sobrepeso</span>.
Patient: <span title="Yes, doctor">Sí, doctor</span>. <span title="I try to eat better">Trato de comer mejor</span> y <span title="walk">caminar</span>, <span title="but my sugar stays high">pero mi azúcar sigue alta</span>.
Physician: <span title="That is a good start">Ese es un buen comienzo</span>. <span title="But diabetes is not just about sugar">Pero la diabetes no es solo el azúcar</span>. <span title="It can also damage">También puede dañar</span> su <span title="heart and kidneys">corazón y sus riñones</span>.
Patient: <span title="My uncle had heart problems">Mi tío tuvo problemas del corazón</span>. <span title="Should I be worried too">¿Debo preocuparme también</span>?
Physician: <span title="We use new tools">Usamos nuevas herramientas</span> para <span title="check your heart and kidney risks">revisar sus riesgos cardíacos y renales</span> <span title="early on">de forma temprana</span>. <span title="We want to prevent problems">Queremos prevenir los problemas</span> <span title="before they start">antes de que empiecen</span>.
Patient: <span title="What can help me stay safe">¿Qué me puede ayudar a mantenerme seguro</span>?
Physician: <span title="Now we have medications">Ahora tenemos medicamentos</span> que <span title="help lose weight">ayudan a bajar de peso</span> y <span title="protect your heart and kidneys">protegen su corazón y sus riñones</span>. <span title="Medications such as">Medicamentos como</span> los <span title="GLP-1 agonists">agonistas de GLP-1</span> o los <span title="SGLT2 inhibitors">inhibidores de SGLT2</span> <span title="work well">funcionan bien</span>.
Patient: <span title="Are they better than my previous pills">¿Son mejores que mis pastillas anteriores</span>?
Physician: <span title="For many people, yes">Para muchas personas, sí</span>. <span title="They do more than lower sugar">Hacen más que bajar el azúcar</span>. <span title="They reduce the risk">Disminuyen el riesgo</span> de <span title="heart and kidney disease">enfermedades del corazón y del riñón</span>.
Patient: <span title="Am I going to need insulin">¿Voy a necesitar insulina</span>?
Physician: <span title="Not always">No siempre</span>. <span title="If you need insulin">Si necesita insulina</span> o <span title="have episodes of low sugar">tiene episodios de azúcar baja</span>, <span title="we can use a CGM">podemos usar un MCG</span> para <span title="monitor your sugar all day">vigilar su azúcar todo el día</span>.
Patient: <span title="What is a CGM">¿Qué es un MCG</span>?
Physician: <span title="The CGM is a small sensor">El MCG es un sensor pequeño</span>. <span title="It measures your sugar">Mide su azúcar</span> <span title="every few minutes">cada pocos minutos</span>. <span title="It helps us see">Nos ayuda a ver</span> <span title="when your sugar goes up or down too much">cuándo su azúcar sube o baja demasiado</span>.
Patient: <span title="Does that mean fewer finger pricks">¿Eso significa menos pinchazos en los dedos</span>?
Physician: <span title="Yes, many fewer">Sí, muchos menos</span>. Y <span title="we check something called">revisamos algo llamado</span> 'tiempo en rango' <span title="to see how you are doing each day">para ver cómo va cada día</span>.
    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

The American Diabetes Association (ADA) Standards of Care in Diabetes say that prevention, cardiorenal risk reduction, and obesity treatment are key goals. The Standards now look at diabetes as part of cardiorenal–metabolic (CKM) health. They say glucose, blood pressure, lipids, weight, kidney function, and heart failure risk all link together. They are not just separate problems.

1. Earlier risk stratification: Adults with overweight/obesity, prediabetes, NAFLD, or established ASCVD/CKD should have earlier and more often checks for dysglycemia and CKM risk. Use ASCVD and kidney risk tools when you can.

2. CGM beyond intensive insulin: ADA Standards support CGM for most people with type 1 diabetes and many insulin-treated people with type 2 diabetes. You may also use CGM in some non–insulin-treated type 2 patients with high hypoglycemia risk or when A1C does not match glucose data.

3. Time in range (TIR): For patients using CGM, aim for TIR ≥70% (70–180 mg/dL) and time below range &lt;4%. These are main glycemic endpoints linked to microvascular risk and add to A1C.

4. Weight- and risk-focused pharmacotherapy: In adults with type 2 diabetes and overweight/obesity, try drugs that help weight loss and give cardiovascular and kidney benefit, like GLP-1 receptor agonists and SGLT2 inhibitors, when cost and access allow. Use them earlier in people with high ASCVD, heart failure, or CKD risk, sometimes even if baseline A1C is at goal or they are not on metformin.

---
DIALOGUE

Narrator: Today, Dr. Smith talks with Mr. Lee about diabetes care.
Physician: Hello, Mr. Lee. I see you have type 2 diabetes and some extra weight.
Patient: Yes, doctor. I try to eat better and walk, but my sugar is still high.
Physician: That is a good start. But diabetes is not just about sugar. It can hurt your heart and kidneys too.
Patient: My uncle had heart problems. Should I worry too?
Physician: We use new tools to check your heart and kidney risks early. We want to stop problems before they start.
Patient: What can help me stay safe?
Physician: We now have medicine that helps lose weight and protects your heart and kidneys. Drugs like GLP-1 agonists or SGLT2 inhibitors work well.
Patient: Are these better than my old pills?
Physician: For many people, yes. They do more than lower sugar. They lower risk for heart and kidney disease.
Patient: Will I need insulin?
Physician: Not always. If you do need insulin or have low sugars, we may use a CGM to watch your sugar all day.
Patient: What is CGM?
Physician: CGM is a small sensor. It checks your sugar every few minutes. It helps us see when your sugar goes too high or low.
Patient: Does that mean fewer finger sticks?
Physician: Yes, much fewer. And we look at something called 'time in range' to see how well you do each day.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 9, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>